Results 51 to 60 of about 45,831 (210)
Case Reports in Oncology, 2023 A 66-year-old male was diagnosed with cT4N0M1b small-cell neuroendocrine carcinoma of the prostate. Four months after the administration of combined androgen blockade, multiple novel metastatic regions in the lung and liver and progression of bone ...
Keisuke Okubo +15 more
doaj +1 more source
Advanced Science, EarlyView.This study identifies mutation‐intolerant genes (MIGs), which are mutationally constrained in tumors despite normal‐tissue variability. Using miDriver, the authors pinpoint MIGs essential for tumor‐intrinsic fitness and immune evasion. Focusing on CHEK1, they show it drives tumor fitness and sculpts an immunosuppressive niche via the MIF–CD74 axis ...
Tao Wang +16 more
wiley +1 more source
Advanced Science, EarlyView.This review elucidates URB design strategies, including genetic and physicochemical modifications, while dissecting the synergistic mechanisms governing spatiotemporal control. It further evaluates applications in targeted drug delivery, gene modulation, and immunotherapy, finally offering perspectives on overcoming translational barriers for clinical ...
Xueyao Wang +5 more
wiley +1 more source
BRCA2: a universal recombinase regulator [PDF]
Oncogene, 2007 Homologous recombination has a dual role in eukaryotic organisms. Firstly, it is responsible for the creation of genetic variability during meiosis by directing the formation of reciprocal crossovers that result in random combinations of alleles and traits.
T, Thorslund, S C, West
openaire +2 more sources
The Challenge of Handling Structured Missingness in Integrated Data Sources
Advanced Intelligent Discovery, EarlyView.As data integration becomes ever more prevalent, a new research question that emerges is how to handle missing values that will inevitably arise in these large‐scale integrated databases? This missingness can be described as structured missingness, encompassing scenarios involving multivariate missingness mechanisms and deterministic, nonrandom ...
James Jackson +6 more
wiley +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Mantle cell lymphoma (MCL) is a B‐cell malignancy with a chronically relapsing clinical course and pronounced genetic heterogeneity. To investigate the clonal dynamics underlying early disease relapse, we performed single‐cell RNA sequencing of paired tumor samples collected at diagnosis and at first relapse. Inference of copy number variants (
Dmitry Manakov +14 more
wiley +1 more source
Environmental and Molecular Mutagenesis, EarlyView.Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons +17 more
wiley +1 more source
International Journal of Cancer, EarlyView.Abstract Genetic tumor risk syndromes (genturis) contribute substantially to the overall cancer burden and provide opportunities for early detection, prevention, and individualized treatment. Yet, many affected individuals remain undiagnosed due to restrictive testing criteria and challenges in variant interpretation.
Mayra Sauer +11 more
wiley +1 more source
Chromatin Remodeling in Response to BRCA2-Crisis
Cell Reports, 2019 Summary: Individuals with a single functional copy of the BRCA2 tumor suppressor have elevated risks for breast, ovarian, and other solid tumor malignancies.
Joshua J. Gruber +8 more
doaj +1 more source
Tạp chí Khoa học Đại học Huế: Khoa học Tự nhiên, 2020 BRCA1 và BRCA2 là hai gen ức chế khối u quan trọng. Việc đột biến hai gen này ở bệnh nhân ung thư biểu mô buồng trứng dòng mầm và dòng sinh dưỡng thì đáp ứng tốt hơn với thuốc ức chế enzyme poly(ADP-ribose) polymerase inhibitor (PARPi).
Ngo Dai Phu +11 more
doaj +1 more source